Q2 FY2026 EarningsQ2 FY26 results were significantly above consensus, with revenue of $11.89M beating the $2.75M estimate due to accelerated BMS collaboration revenue recognition. GAAP EPS of -$0.15 exceeded the -$0.27 mean expectation, driven by lower-than-expected operating expenses following a major workforce reduction. A May 2026 public offering strengthened the balance sheet to $211.6M in cash, extending the runway into 2028.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Editas Medicine(EDIT) the Revenue is 11.89 M (+232.3%), Beat estimate;the EBIT is -18.55 M (+64%), Beat estimate;the EPS is -0.15 (+76.19%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B232.31%
0.00B23.13%
+0.01B255.44%
EBITExceed expectations
-0.02B64.00%
-0.03B44.42%
+0.01B19.58%
EPSExceed expectations
-0.1576.19%
-0.270457.08%
+0.120419.11%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf